Background The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is
generally poor. Recently, new classes of drugs (eg immune checkpoint inhibitors and small …

A unique collaboration of multidisciplinary experts from the European Dermatology Forum
(EDF), the European Association of Dermato-Oncology (EADO), and the European …

A unique collaboration of multidisciplinary experts from the European Dermatology Forum,
the European Association of Dermato-Oncology and the European Organization for …

Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and
causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts …

Expression of PD-1 ligands by tumors and interaction with PD-1–expressing T cells in the
tumor microenvironment can result in tolerance. Therapies targeting this coinhibitory axis …

Background Patients with melanoma harbouring Val600 BRAF mutations benefit from
treatment with BRAF inhibitors. However, no targeted treatments exist for patients with BRAF …

Purpose Dabrafenib (GSK2118436) is a potent inhibitor of mutated BRAF kinase. Our
multicenter, single-arm, phase II study assessed the safety and clinical activity of dabrafenib …

Blocking autophagy with hydroxychloroquine (HCQ) augments cell death associated with
alkylating chemotherapy in preclinical models. This phase I study evaluated the maximum …

Introduction Melanoma is the most serious form of skin cancer causing most of the skin
cancer-related deaths. The incidence of melanoma has risen so dramatically over past few …

Purpose Elesclomol, an investigational first-in-class compound, induces oxidative stress,
triggers mitochondrial-induced apoptosis in cancer cells, and shows synergy with taxanes in …